Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Director Robert Paul Harris sold 150,000 shares of the stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $5.82, for a total transaction of $873,000.00. Following the sale, the director now directly owns 669,094 shares in the company, valued at $3,894,127.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) opened at 5.18 on Thursday. Aralez Pharmaceuticals Inc. has a 1-year low of $3.10 and a 1-year high of $8.59. The stock’s market capitalization is $337.95 million. The firm has a 50-day moving average of $5.09 and a 200-day moving average of $4.17.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The business earned $12.60 million during the quarter, compared to analyst estimates of $9.70 million. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. The business’s revenue was up 142.3% compared to the same quarter last year. Equities research analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.05) EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of ARLZ. Alps Advisors Inc. raised its position in shares of Aralez Pharmaceuticals by 24.9% in the second quarter. Alps Advisors Inc. now owns 89,850 shares of the company’s stock worth $297,000 after buying an additional 17,920 shares during the period. Bank of Montreal Can purchased a new position in shares of Aralez Pharmaceuticals during the second quarter worth about $100,000. Franklin Street Advisors Inc. NC raised its position in shares of Aralez Pharmaceuticals by 184.0% in the second quarter. Franklin Street Advisors Inc. NC now owns 168,991 shares of the company’s stock worth $558,000 after buying an additional 109,491 shares during the period. Rubric Capital Management LLC purchased a new position in shares of Aralez Pharmaceuticals during the first quarter worth about $843,000. Finally, Deerfield Management Co. purchased a new position in shares of Aralez Pharmaceuticals during the first quarter worth about $5,838,000. Institutional investors own 49.63% of the company’s stock.

A number of research analysts recently weighed in on the stock. Guggenheim reaffirmed a “buy” rating and issued a $12.00 price target on shares of Aralez Pharmaceuticals in a research note on Monday, August 15th. Chardan Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aralez Pharmaceuticals in a research note on Friday, September 16th.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.